FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine, namely to gynaecology, and can be used for a method of prevention and/or treatment of urogenital atrophy in women, including the vaginal introduction of pharmaceutical compositions with estriol, as well as for the application of estriol in the production of a pharmaceutical composition with a possibility of self-restriction of estriol absorption. The said women have the high possibility of development of a cardiovascular pathology, or suffer or suffered from the cardiovascular pathology. Estriol is introduced in a dose, smaller or equal to 0.1 mg/day. An area under the estriol concentration curve depending on the time constitutes less than 500 pg/ml·h after the introduction of repeated doses one time per day for the time period from 1 to 4 weeks.
EFFECT: group of inventions provides efficient and safe treatment.
24 cl, 7 tbl, 1 dwg
Title | Year | Author | Number |
---|---|---|---|
TREATING VAGINAL ATROPHY IN FEMALES AT RISK OF TUMORAL PATHOLOGY | 2009 |
|
RU2504381C2 |
USE OF LOW-DOSE OESTRIOL | 2008 |
|
RU2483734C2 |
DROSPYRENON FOR REPLACEMENT HORMONOTHERAPY | 2001 |
|
RU2275198C2 |
DROSPIRENONE FOR HORMONAL REPLACEMENT THERAPY | 2005 |
|
RU2402331C2 |
METHOD FOR ENHANCING OF TESTOSTERONE AND ANALOGOUS STEROID LEVELS IN FEMALES | 2001 |
|
RU2286787C2 |
USING INTRAVAGINAL INSULIN SENSITISERS | 2010 |
|
RU2567334C2 |
PHARMACEUTICAL COMPOSITIONS AND METHODS BASED ON OESTRADIOL FOR INTRAVAGINAL INTRODUCTION | 2014 |
|
RU2713888C2 |
METHOD FOR SUPPORTING AMENORRHEA IN WOMEN SUBJECTING CONSTANT ADMINISTRATION OF PROGESTIN AND PHARMACEUTICAL COMPOSITION FOR ITS REALIZATION | 1998 |
|
RU2261099C2 |
METHOD FOR VAGINAL ATROPHY TREATMENT IN WOMEN IN POSTMENOPAUSE CONSIDERING VAGINAL EPITHELIUM AND MICROBIOCENOSIS STATE | 2017 |
|
RU2636619C1 |
PHARMACEUTICAL COMPOSITION FOR TREATING UROGENITAL DISEASES | 2008 |
|
RU2375064C1 |
Authors
Dates
2015-07-10—Published
2009-08-07—Filed